Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or AsciminibElias Jabbour, H. Kantarjian, Anna Turkina et al.|JAMA Oncology|2024Cited by 26
Reports to FDA of fatal anaphylaxis associated with intravenous iron productsLynda McCulley, Peter Waldron, Sarah Harris et al.|American Journal of Hematology|2016Cited by 24